NR3C2 and diabetic kidney disease: Increasing evidence supports that employing new classes of medication, such as sodium-glucose cotransporter 2 (SGLT2is) and non-steroid mineralocorticoid receptor antagonist (ns-MRA) could potentially reduce the predefined composite renal outcomes and cardiovascular (CV) outcomes in patients with DKD.